148 related articles for article (PubMed ID: 34764112)
1. Atezolizumab-induced scleroderma: a rare complication.
Grant C; Chalasani V; Uchin JM; Dore A
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34764112
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic Scleroderma: Are There Any Clues?
Jedlickova H; Durčanská V; Vašků V
Acta Dermatovenerol Croat; 2016 Apr; 24(1):78-80. PubMed ID: 27149136
[TBL] [Abstract][Full Text] [Related]
3. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
[TBL] [Abstract][Full Text] [Related]
7. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
[TBL] [Abstract][Full Text] [Related]
8. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D; Reck M; Moro-Sibilot D; Mazieres J; Gadgeel S; Morris S; Cardona A; Mendus D; Ballinger M; Rittmeyer A; Peters S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737340
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
Li DN; Lu WQ; Yang BW; Zhang LY; Jin B; Wang S; Che XF; Li C; Liu YP; Qu XJ
Front Immunol; 2021; 12():666909. PubMed ID: 34149702
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Morphological Characteristics of Anti-Programmed Death Ligand 1-Associated Retinopathy: Expanding the Spectrum of Acute Macular Neuroretinopathy.
Ramtohul P; Freund KB
Ophthalmol Retina; 2020 Apr; 4(4):446-450. PubMed ID: 31926948
[TBL] [Abstract][Full Text] [Related]
11. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS; Giaccone G; de Marinis F; Reinmuth N; Vergnenegre A; Barrios CH; Morise M; Felip E; Andric Z; Geater S; Özgüroğlu M; Zou W; Sandler A; Enquist I; Komatsubara K; Deng Y; Kuriki H; Wen X; McCleland M; Mocci S; Jassem J; Spigel DR
N Engl J Med; 2020 Oct; 383(14):1328-1339. PubMed ID: 32997907
[TBL] [Abstract][Full Text] [Related]
13. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Ishi A; Tanaka I; Iwama S; Sakakibara T; Mastui T; Kobayashi T; Hase T; Morise M; Sato M; Arima H; Hashimoto N
Endocr J; 2021 May; 68(5):613-620. PubMed ID: 33790087
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
[TBL] [Abstract][Full Text] [Related]
16. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.
Fujita K; Uchida N; Yamamoto Y; Kanai O; Okamura M; Nakatani K; Sawai S; Mio T
Anticancer Res; 2019 Jul; 39(7):3917-3921. PubMed ID: 31262921
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer.
Hellmann MD; Gettinger S; Chow LQM; Gordon M; Awad MM; Cha E; Gong X; Zhou G; Walker C; Leopold L; Heist RS
Int J Cancer; 2020 Oct; 147(7):1963-1969. PubMed ID: 32141617
[TBL] [Abstract][Full Text] [Related]
18. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
Furuya N; Nishino M; Wakuda K; Ikeda S; Sato T; Ushio R; Tanzawa S; Sata M; Ito K
Thorac Cancer; 2021 Mar; 12(5):613-618. PubMed ID: 33448648
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer.
Kichloo A; Albosta MS; Jamal SM; Aljadah M; Wani F; Selene I; Singh J; Taj A
J Investig Med High Impact Case Rep; 2020; 8():2324709620965010. PubMed ID: 33047629
[TBL] [Abstract][Full Text] [Related]
20. The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer.
Manzo A; Carillio G; Montanino A; Sforza V; Palumbo G; Esposito G; Costanzo R; Sandomenico C; La Manna C; Martucci N; La Rocca A; De Luca G; Piccirillo MC; De Cecio R; Botti G; Totaro G; Muto P; Picone C; Normanno N; Morabito A
Expert Opin Drug Saf; 2020 Jul; 19(7):775-783. PubMed ID: 32400223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
